Age (years)
|
median (range)
|
66 (51-87)
|
---|
Histology
|
Ductal/other
| 48/9 |
Estrogen receptor
|
RE+/RE-
| 52/5 |
Progesteron receptor
|
RP+/RP-
| 45/12 |
Tumor stage
|
Tis/T1/T2
| 1/48/8 |
Nodal stage
|
N0/N1
| 54/3 |
Chemotherapy
|
yes/no
| 15/42 |
 |
CMF
| 5 |
 |
FEC
| 5 |
 |
EC
| 1 |
 |
EC+ Docetaxel | 4 |
Hormone-therapy
|
yes/no
| 52/5 |
-
Abbreviations: CMF: Cyclophosphamide (600 mg/m2, Methotrexate 40 mg/m2, 5-FU 600 mg/m2 d 1 and d 8 q 4 weeks Ă— 6); FEC (5-FU 600 mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 d 1 q 3 weeks Ă— 6); EC (Epirubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 d1 q 3 weeks Ă— 4); EC+ Docetaxel : EC followed by Docetaxel (100 mg/m2 d1 q 3 weeks Ă— 4)